Semaglutide and antidepressants can be prescribed together. An antidepressant prescription alone does not rule out semaglutide, and semaglutide labels do not name a direct interaction with the common antidepressants discussed below. The practical questions are whether tablets are being absorbed reliably, how mood is doing, and whether the antidepressant itself affects weight. Any conversation about changing a psychiatric medication belongs with the prescriber of that medication.
Can semaglutide and antidepressants be used together?
The answer depends on the whole medication list, but these names do not automatically make the combination unsuitable:
| Antidepressant | What the name means | The practical distinction |
|---|---|---|
| Sertraline (Zoloft), escitalopram (Lexapro), paroxetine (Paxil) | SSRIs, antidepressants that increase the availability of serotonin, a brain messenger | No specific interaction with these drugs is named in semaglutide labeling |
| Venlafaxine (Effexor), duloxetine (Cymbalta) | SNRIs, antidepressants that affect serotonin and another messenger, norepinephrine | The same monitoring question applies to tablets |
| Bupropion (Wellbutrin) | An antidepressant that works through different brain messengers | Its weight pattern differs from several other antidepressants |
That is a reading of the labels, not proof that every pairing has been tested. The Ozempic interaction section focuses on certain diabetes medicines and oral medicines, meaning those taken by mouth. A pharmacokinetic interaction means one drug changes how much of another reaches or remains in the body; none is specifically listed for these antidepressants.
Does slower digestion make an antidepressant less effective?
It can affect how a tablet is absorbed, but slower digestion does not automatically mean an antidepressant stops working.
As of September 10, 2026, the day this article was written, the Wegovy label marked “Revised: 6/2026” states in section 7.2: “WEGOVY causes a delay of gastric emptying.” That means food leaves the stomach more slowly; the label says this can affect oral medicines and calls for monitoring their effects.
The same section reports no absorption effect for the oral medicines tested with weekly semaglutide injections. It does not name antidepressants as tested drugs. Vomiting also matters because a tablet may not stay down.
The useful discussion is about symptoms, timing and the exact formulation, including whether semaglutide is a tablet or an injection. The broader semaglutide drug interaction guide covers other medicines.
What did the STEP and SELECT trials allow?
People taking antidepressants were included in STEP, the weight-management trial program. In a later analysis of STEP 1–3 and 5, about 1 in 7 participants—539 of 3,683—were taking one when they enrolled.
In STEP 1, that group averaged 15.7% weight loss with semaglutide versus 0.2% with placebo, an inactive comparison treatment, over 68 weeks. Those are study averages, not an individual forecast. The analysis by Kushner and colleagues in Obesity, 2024 found weight reductions in participants both with and without antidepressant use.
There were meaningful boundaries. STEP excluded people with recent severe major depression or answers to a mood questionnaire suggesting moderately severe or severe depression. It cannot tell us that every person with active psychiatric symptoms would have the same experience.
SELECT, a heart-outcomes trial, excluded severe psychiatric illness when investigators thought it could prevent someone from following the study plan. Its 2025 safety report describes that restriction, rather than a blanket exclusion for antidepressants. Neither trial provides a separate interaction test for every psychiatric medicine.
What does the FDA mood review mean here?
As of September 10, 2026, the day this article was written, the FDA's January 13, 2026 safety communication reports no increased risk of suicidal thoughts or behavior after its expanded review. Its preliminary 2024 review had found no causal evidence but left uncertainty about a small risk; the later review led to a request to remove the warning from Wegovy, Saxenda and Zepbound.
These are GLP-1 medicines, drugs that act on a gut-hormone signal involved in appetite and blood sugar. The finding does not make semaglutide a depression treatment. The fuller evidence is in does semaglutide cause depression?.
Tirzepatide, the drug in Zepbound, can also come up as a weight-management option. As of September 10, 2026, the day this article was written, its label marked “Revised: 8/2026” likewise calls for attention to oral medicines because stomach emptying slows. Choosing it does not remove that question, and its label advises against combining it with semaglutide.
Do antidepressants change the weight picture?
They can, and the specific drug matters. A review of 116 studies by Serretti and Mandelli, Journal of Clinical Psychiatry, 2010 associated mirtazapine and paroxetine with greater weight gain. Bupropion was associated with some weight loss, although individual responses varied.
Newer evidence adds perspective. A 2024 Annals of Internal Medicine study of 183,118 adults starting antidepressants found less average weight gain with bupropion than sertraline. The difference at six months was about half a pound, or 0.22 kilograms. That was a comparison between antidepressants, not a semaglutide study, and less gain is not necessarily weight loss.
A weight trend can therefore reflect more than one medicine. It does not, by itself, show that an antidepressant is blocking semaglutide or that a psychiatric prescription needs changing.
What has newer research added?
As of September 10, 2026, the day this article was written, a 72-person trial published online November 10, 2025, in Med has tested oral semaglutide added to usual care for major depression. Over 16 weeks, it did not improve the main measure of thinking skills or change depression severity or suicidal-thought frequency. This small study cannot settle long-term combination safety.
As of September 10, 2026, the day this article was written, a July 24, 2026 case report in Frontiers in Psychiatry also described depression returning after oral semaglutide was restarted in one person who continued vortioxetine and bupropion, two antidepressants. One case cannot establish cause or estimate risk, and the authors acknowledged that semaglutide had not fully cleared before restarting. It is a reason to take individual mood changes seriously, not a reason to alter treatment without the prescriber.
What will a provider want to know?
The intake needs the names, doses and formulations of all psychiatric medicines, including recent changes and who prescribes them. Current mood, past severe episodes, any suicidal thoughts, and a history of eating disorders help establish what needs closer review.
Appetite and weight history matter too: when changes began, whether nausea disrupts meals, and whether vomiting makes tablets difficult to keep down. A provider can then plan follow-up around the person's actual routine. New or worsening depression warrants prompt clinical contact; suicidal thoughts require immediate help regardless of the suspected cause.
The first-visit guide explains the intake process. The prescriber sets the semaglutide dose, and psychiatric medication decisions remain with the clinician managing that treatment.
How the prescription route fits
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded means prepared by a pharmacy for an individual prescription. The FDA explains this distinction; the studies above did not test Promise's formulation.
A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision is between the patient and the doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies. A useful review brings weight goals and existing mental-health care into the same conversation.
